CYTOKINETICS INC (CYTK)

As of 14 August 2026, short interest in CYTK is 16,323,712 shares, down 728,269 shares over the last month. Over the last 48 readings it ranged from 12,948,508 shares (28 November 2025) to 18,207,015 shares (30 August 2024). At the reported average volume of 2.1M shares a day that is 7.7 days to cover, elevated.

<iframe src="https://xoomar.com/embed/stocks/cytk" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of CYTK volume is 62.2%, down 0.5 points over the last five sessions. Over the last 52 readings it ranged from 30.2% (12 August 2026) to 86.4% (29 July 2026). The latest reading is 4.4 points above the 30-session average of 57.9%, on 659K shares reported.

As of 12 August 2026, the fails-to-deliver balance in CYTK is 10,465 shares, up 9,269 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (14 April 2026) to 95,167 shares (6 April 2026).

Insiders at CYTK reported 13 open-market sells worth $5.7M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Landry Robert E on 2026-09-11.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

3 Form 144 notices on file for CYTK worth $2.4M at the prices reported; 3 in the last 90 days worth $2.4M. Latest: ROBERT LANDRY filed on 2026-09-11 to sell 2,000 shares ($147K) from 2026-09-11.

3 holders above 5% have filed on CYTK, all on Schedule 13G (passive). The largest reported stake is Wellington Management Group LLP at 5.1% of the class (7,116,724 shares), filed 2026-08-13 for an event on 2026-06-30.

8 of the 30 tracked managers held CYTK at their latest 13F, $541.0M in total at quarter-end prices. Citadel Advisors is the largest at $167.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 3 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) CYTOKINETICS INC reported revenue of $28.6M, down 57.1% from the same quarter a year earlier, and net loss of $198.8M (-1.50 diluted EPS). In FY 2025 it generated -$510.0M of operating cash flow. As of 2026-06-30, cash was $255.3M against $248.2M of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-04 from the cover page.